ORNAV Orion Oyj

110.78USD101.00 EUR · HEL-0.39%Mkt Cap: 15.54B USDP/E: 21.58

Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. It offers pharm…

Key Statistics

Company
Market Cap15.54B USD
Enterprise Value15.53B USD
Revenue (TTM)2.39B USD
Gross Profit1.33B USD
Net Income (TTM)548.73M USD
Revenue/Share16.96 USD
Last Price110.78 USD
Fiscal Year EndDec 2025
MR QuarterSep 2026
Employees4.2K
CountryFI
SectorHealthcare
IndustryDrug Manufacturers - General
ISINFI0009014369
Valuation
P/E (Trailing)21.58
P/E (Forward)—
PEG5.73
EV/EBITDA16.01
EV/Revenue6.50
P/S6.51
P/B10.14
EPS (TTM)5.13 USD
EPS (Forward)—
52W Range
63.6194% of range113.85
52W High113.85 USD
52W Low63.61 USD
Profitability
Gross Margin64.20%
Oper. Margin38.11%
EBITDA Margin40.63%
Profit Margin26.48%
ROE38.95%
ROA24.89%
ROIC35.08%
ROCE43.39%
Growth
Revenue Growth28.10%
Earnings Growth75.00%
Cash Flow & Leverage
Operating CF347.47M USD
CapEx (TTM)107.05M USD
FCF Margin12.47%
FCF Yield1.92%
Net Debt-20.62M USD
Net Debt/EBITDA-0.02
Net Debt/FCF-0.07
Balance Sheet
Debt/Equity0.24
Current Ratio2.72
Quick Ratio1.61
Book Value/Sh10.93 USD
Cash/Share1.13 USD
Dividends
Fwd Div Rate1.97 USD
Trail. Div Rate1.97 USD
Div. Yield1.78%
5Y Avg Yield2.90%
Payout Ratio36.75%
Ex-Div DateOct 19, 2026
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.31.15M
Float122.99M
Insiders32.89%
Institutions8.10%
Technical
SMA 5097.86 (+13.2%)
SMA 20083.77 (+32.2%)
Beta0.23
S&P 52W Chg12.00%
Avg Vol (30d)9.71K
Avg Vol (10d)8.09K
Technical Indicators
RSI (14)70.9
MACD3.6619
MACD Signal4.2021
MACD Hist.-0.5402
BB Upper115.87 USD
BB Middle109.44 USD
BB Lower103.02 USD
BB Width11.73%
ATR (14)2.327 USD
Vol Ratio (20d)0.30x

About Orion (HEL: ORNAV)

›

Orion (HEL: ORNAV) is listed on Nasdaq Helsinki, where its shares trade in EUR. It belongs to the Drug Manufacturers - General industry, part of the Healthcare sector, and reports about 4,215 employees.

The shares were at 101.00 EUR on 19 November 2026, up 77.1% over 52 weeks. Its 52-week range is 58.00 EUR to 103.80 EUR: the price is 2.7% below the high and 74.1% above the low.

At a market capitalisation of 14.16B EUR, it trades at 21.6 times trailing earnings. The median trailing P/E of its 19 largest Drug Manufacturers - General peers is 26.0, a discount of 17% for ORNAV. It pays a dividend yielding 1.78% (it pays out 37% of its earnings), against a median of 2.43% among the dividend payers in that peer group.

Orion reports return on equity of 38.9%, an operating margin of 38.1% and revenue up 28.1% year over year.

It holds more cash than debt, a net cash position of 18.80M EUR. Its Piotroski F-score is 6 out of 9, an average reading of its financial health.